Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06590467 · ClinicalTrials.gov registry record

Abbott Structural Heart Device Registry

A clinical trial of Heart Diseases and Valvular Heart Disease, sponsored by Abbott Medical Devices.

Recruiting
Registry status
2,500
Enrollment target
20
Study locations

NCT06590467: Recruiting study of Heart Diseases and Valvular Heart Disease, sponsored by Abbott Medical Devices.

NCT06590467 is a study of Heart Diseases and Valvular Heart Disease that is actively recruiting participants, run by Abbott Medical Devices. The registered enrollment target is 2,500 participants, below the 5,503-participant average among 85 other Heart Diseases trials with a reported enrollment target (55% lower). The trial reports 20 study locations across 17 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06590467, a study of Heart Diseases and Valvular Heart Disease, is actively recruiting participants, sponsored by Abbott Medical Devices.

RECRUITING
Registry status
2,500 participants
Enrollment target
20
Study locations

Study Summary

The Abbott Structural Heart (SH) Registry is being conducted to confirm the safety and performance of Abbott's SH devices in a post-market, real-world setting. The Registry primarily involves gathering data from routine hospital practices and standard-of-care (SOC) procedures administered to patients. All devices used in these procedures must be commercially available to the participating site. A list of specific devices covered by the Registry are available upon request from the Sponsor. Data generated by the Registry will be used to meet regulatory requirements, such as the European Union Medical Device Regulations 2017/745, that require active post-market clinical follow-up (PMCF) for all commercially available devices.

Primary Outcome

The primary safety endpoint will be the proportion of subjects with device- and/or procedure-related serious adverse events (SAEs) occurring within 7 days of the procedure.

Interventions

  • DEVICE Amplatzer™ Occlusion Devices
  • DEVICE Epic™ Surgical Tissue Heart Valve devices

Study Locations (20)

Other

  • Centre Médico Chirurgical Marie Lannelongue - Le Plessis-Robinson
  • Hopital Haut Leveque - Pessac
  • Schüchtermann-Schiller´sche Kliniken GmbH & Co. KG - Bad Rothenfelde

Lombardy

  • IRCCS Policlinico San Donato - Cardio - San Donato Milanese
  • Policlinico San Donato - San Donato Milanese

New Jersey

  • Robert Wood Johnson University Hospital - New Brunswick

New York

  • Mount Sinai Hospital - New York

Pennsylvania

  • UPMC - Pittsburgh

Virginia

  • Sentara Norfolk General Hospital - Norfolk

Southern Denmark

  • Odense University Hospital - Odense

Tartu

  • Tartu University Hospital - Tartu

Trial Details

FieldValue
Enrollment Target 2,500 participants
Start Date 2024-08-21
Est. Completion 2039-11
Abbott Medical Devices

261 total trials

What NCT06590467 shows while recruiting

NCT06590467 is an observational study that tracks outcomes without assigning an intervention. Its 2,500 participants enrollment target places it among the larger protocols in the corpus, below the 5,503-participant average among 85 other Heart Diseases trials with a reported enrollment target (55% lower).

The record links to 6 conditions, with Heart Diseases appearing as the primary indexed condition, and to 2 interventions - of which Amplatzer™ Occlusion Devices is the first listed.

NCT06590467 names 20 study sites across 17 states, led by Other, Lombardy, New Jersey.

Frequently Asked Questions

What is clinical trial NCT06590467 about?

NCT06590467 is a clinical study titled "Abbott Structural Heart Device Registry". The Abbott Structural Heart (SH) Registry is being conducted to confirm the safety and performance of Abbott's SH devices in a post-market, real-world setting. The Registry primarily involves gathering data from routine hospital practices and standard-of-care (SOC) procedures administered to patient...

What is the current status of trial NCT06590467?

This trial is currently recruiting. The enrollment target is 2,500 participants. The study started on 2024-08-21. Estimated completion is 2039-11.

What conditions does trial NCT06590467 study?

This clinical trial studies the following conditions: Heart Diseases, Valvular Heart Disease, PFO - Patent Foramen Ovale, ASD - Atrial Septal Defect, VSD - Muscular Ventricular Septal Defect.

What interventions are being tested in trial NCT06590467?

The interventions under investigation include: Amplatzer™ Occlusion Devices (DEVICE), Epic™ Surgical Tissue Heart Valve devices (DEVICE).

Who is sponsoring clinical trial NCT06590467?

This trial is sponsored by Abbott Medical Devices, which has 261 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06590467 being conducted?

This trial has 20 study locations across New Jersey, New York, Pennsylvania, Virginia, Southern Denmark. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Heart Diseases

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT06590467's enrollment target sits among peer trials

2,500 15th of 85 higher than 71 of 85 other Heart Diseases trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Heart Diseases trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00001160 · 2,500 participants

    Studies on Tumors of the Thyroid

  • NCT01904188 · 2,500 participants

    Clinical Microbial Species & Antibiotic Resistance ID in ED Patients Presenting With Infection - is Rapid ID Possible & Accurate?

  • NCT02257229 · 2,500 participants

    Prospective Evaluation of Treatment for Clubfoot

  • NCT02530658 · 2,500 participants

    Next Generation Sequencing of Normal Tissues Prospectively in Pediatric Oncology Patients

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT06590467, the US trial registry maintained by the National Library of Medicine. NCT06590467 (large enrollment · wide site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.